Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inhaled Dornase Alfa for Treatment of ARDS in Patients With SARS-CoV-2

NCT04402970 is registered in ClinicalTrials.gov with University of Missouri-Columbia as lead sponsor.

NCT NCT04402970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04402970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inhaled Dornase Alfa for Treatment of ARDS in Patients With SARS-CoV-2
Lead sponsor
University of Missouri-Columbia
Phase
Phase 3
Overall status
Completed
Start date
June 19, 2020
Completion date
December 31, 2020
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ards, sars-cov 2